Vero Biotech Raises $30 Million To Accelerate Commercialization Of Its Innovative Tankless Inhaled Nitric Oxide Delivery System
Vero Biotech Raises $30 Million To Accelerate Commercialization Of Its Innovative Tankless Inhaled Nitric Oxide Delivery System
01/11/23, 1:00 PM
Location
atlantaMoney raised
$30 million
Industry
biotechnology
health care
Investors
Patrick Lally, Partner Of Petrichor, Petrichor
VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced the successful close of a $30 million financing with Petrichor, a leading healthcare-dedicated growth capital provider. The proceeds will support further development and commercialization of VERO Biotech's GENOSYL Delivery System (DS), a tankless inhaled nitric oxide (iNO) delivery system. The third generation of the GENOSYL DS was recently approved by the FDA and represents a breakthrough in iNO technology benefitting both providers and patients. Patrick Lally, Partner of Petrichor, has joined the VERO Biotech Board of Directors
Company Info
Location
387 technology cir. nw
atlanta, georgia, united states
Additional Info
Vero biotech is an emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions.
At Vero Biotech, our mission is to improve the lives of patients by leading the development of innovative technologies for inhaled NO delivery in the acute care hospital setting and beyond, wherever Nitric Oxide treatment is needed. We strive to exceed customer expectations in terms of safety, efficacy, and growth by focusing on the science, development, and commercialization of our innovations.